{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-019006","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.845424+00:00","generated_at":"2026-05-17T02:34:00.129437+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biofrontera closes purchase of Ameluz/RhodoLED US assets, reduces earnout to 12-15%","bullets":["Acquired all U.S. assets and rights to Ameluz and RhodoLED, including NDA, patents, manufacturing, and personnel.","New earnout structure: 12% of net sales up to $65M, 15% above; replaces prior 25-35% perpetual payment.","Closing released final $2.5M of $11M financing led by existing investors Rosalind Advisors and AIGH.","Biofrontera AG receives 10% post-money equity stake in Biofrontera Inc., aligning long-term interests.","Company expects full asset and personnel transfer by late Q4 2025 or early Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-019006","json":"https://secwatch.observer/filing/0001493152-25-019006.json","markdown":"https://secwatch.observer/filing/0001493152-25-019006.md","text":"https://secwatch.observer/filing/0001493152-25-019006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315225019006/0001493152-25-019006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315225019006/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:34:00.129437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}